{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T18:13:24Z","timestamp":1793643204394,"version":"4.5.1"},"reference-count":80,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,9,22]],"date-time":"2021-09-22T00:00:00Z","timestamp":1632268800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    Immune checkpoint inhibitor therapies and allogeneic hematopoietic cell transplant (alloHCT) represent two distinct modalities that offer a chance for long-term cure in a diverse array of malignancies and have experienced many breakthroughs in recent years. Herein, we review the CD27-CD70 co-stimulatory pathway and its therapeutic potential in 1) combination with checkpoint inhibitor and other immune therapies and 2) its potential ability to serve as a novel approach in graft-\n                    <jats:italic>versus<\/jats:italic>\n                    -host disease (GVHD) prevention. We further review recent advances in the understanding of GVHD as a complex immune phenomenon between donor and host immune systems, particularly in the early stages with mixed chimerism, and potential novel therapeutic approaches to prevent the development of GVHD.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2021.715909","type":"journal-article","created":{"date-parts":[[2021,9,30]],"date-time":"2021-09-30T23:23:31Z","timestamp":1633044211000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":25,"title":["Targeting the CD27-CD70 Pathway to Improve Outcomes in Both Checkpoint Immunotherapy and Allogeneic Hematopoietic Cell Transplantation"],"prefix":"10.3389","volume":"12","author":[{"given":"Forat","family":"Lutfi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Sunshine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuefang","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,9,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2016.09.023","article-title":"The Biology of Chronic Graft-Versus-Host Disease: A Task Force Report From the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-Versus-Host Disease","author":"Cooke","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-018-0340-0","article-title":"Ocular Graft-Versus-Host Disease After Hematopoietic Cell Transplantation: Expert Review From the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT","volume":"54","author":"Inamoto","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.12.024","article-title":"Improved Treatment-Related Mortality and Overall Survival of Patients With Grade IV Acute GVHD in the Modern Years","volume":"22","author":"El-Jawahri","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-01-514786","article-title":"Acute Graft-Versus-Host Disease: A Bench-to-Bedside Update","volume":"124","author":"Holtan","year":"2014","journal-title":"Blood"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.172.12.7393","article-title":"Host Dendritic Cells Alone Are Sufficient to Initiate Acute Graft-Versus-Host Disease","volume":"172","author":"Duffner","year":"2004","journal-title":"J Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-02-697250","article-title":"Alloantigen Presentation and Graft-Versus-Host Disease: Fuel for the Fire","volume":"127","author":"Koyama","year":"2016","journal-title":"Blood"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1172\/JCI0214989","article-title":"Preterminal Host Dendritic Cells in Irradiated Mice Prime CD8+ T Cell\u2013Mediated Acute Graft-Versus-Host Disease","volume":"109","author":"Zhang","year":"2002","journal-title":"J Clin Invest"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.177.9.5968","article-title":"Subepithelial Myofibroblasts are Novel Nonprofessional APCs in the Human Colonic Mucosa","volume":"177","author":"Saada","year":"2006","journal-title":"J Immunol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1016\/j.exphem.2016.08.001","article-title":"Immunological Properties of Bone Marrow Microenvironment 1 Year After Allogeneic Hematopoietic Stem Cell Transplantation","volume":"44","author":"Ciomber","year":"2016","journal-title":"Exp Hematol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1097\/MOH.0000000000000148","article-title":"Fight or Flight: Regulation of Emergency Hematopoiesis by Pyroptosis and Necroptosis","volume":"22","author":"Croker","year":"2015","journal-title":"Curr Opin Hematol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1126\/science.285.5426.412","article-title":"Prevention of Graft Versus Host Disease by Inactivation of Host Antigen- Presenting Cells","volume":"285","author":"Shlomchik","year":"1999","journal-title":"Sci (80- )"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-cellbio-020520-114601","article-title":"The Source and Dynamics of Adult Hematopoiesis: Insights From Lineage Tracing","volume":"36","author":"Pucella","year":"2020","journal-title":"Annu Rev Cell Dev Biol"},{"key":"B13","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.196.Supp.62.13","article-title":"NLRP12 Limits Tnf\u03b1-Induced Apoptosis of Monocyte Progenitor Cells During Emergency Hematopoiesis","volume":"196","author":"Linz","year":"2016","journal-title":"J Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1053\/bbmt.2002.v8.pm12171484","article-title":"Nonmyeloablative Bone Marrow Transplantation From Partially HLA-Mismatched Related Donors Using Posttransplantation Cyclophosphamide","volume":"8","author":"O\u2019Donnell","year":"2002","journal-title":"Biol Blood Marrow Transplant"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1701331","article-title":"Tacrolimus: A New Agent for the Prevention of Graft-Versus-Host Disease in Hematopoietic Stem Cell Transplantation","volume":"22","author":"Jacobson","year":"1998","journal-title":"Bone Marrow Transplant"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1703633","article-title":"Mycophenolate Mofetil for the Treatment of Acute and Chronic GVHD Is Effective and Well Tolerated But Induces a High Risk of Infectious Complications: A Series of 21 BM or PBSC Transplant Patients","volume":"30","author":"Baudard","year":"2002","journal-title":"Bone Marrow Transplant"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-019-0731-x","article-title":"Ruxolitinib in Refractory Acute and Chronic Graft-Versus-Host Disease: A Multicenter Survey Study","volume":"55","author":"Escamilla G\u00f3mez","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1917635","article-title":"Ruxolitinib for Glucocorticoid-Refractory Acute Graft-Versus-Host Disease","volume":"382","author":"Zeiser","year":"2020","journal-title":"N Engl J Med"},{"key":"B19","unstructured":"FDA Package Insert2014"},{"key":"B20","doi-asserted-by":"publisher","first-page":"8005","DOI":"10.1200\/JCO.2020.38.15_suppl.8005","article-title":"KEYNOTE-204: Randomized, Open-Label, Phase III Study of Pembrolizumab (Pembro) Versus Brentuximab Vedotin (BV) in Relapsed or Refractory Classic Hodgkin Lymphoma (R\/R cHL)","volume":"38","author":"Kuruvilla","year":"2020","journal-title":"J Clin Oncol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"e192535","DOI":"10.1001\/jamanetworkopen.2019.2535","article-title":"Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs","volume":"2","author":"Haslam","year":"2019","journal-title":"JAMA Netw Open"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/nrd4476","article-title":"The Immune Checkpoint Inhibitors: Where are We Now","volume":"13","author":"Webster","year":"2014","journal-title":"Nat Rev Drug Discovery"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12964-016-0160-z","article-title":"T Cell Exhaustion: From Pathophysiological Basics to Tumor Immunotherapy","volume":"15","author":"Catakovic","year":"2017","journal-title":"Cell Commun Signal"},{"key":"B24","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.tips.2018.10.008","article-title":"MDSC; the Most Important Cell You Have Never Heard of","volume":"40","author":"Tesi","year":"2019","journal-title":"Trends Pharmacol Sci"},{"key":"B25","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/B978-0-12-802585-7.00005-4","article-title":"Costimulation in Lymphomas and Cancers","volume-title":"Developing Costimulatory Molecules for Immunotherapy of Diseases","author":"Mir","year":"2015"},{"key":"B26","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1007\/s12038-020-0020-2","article-title":"T Cell Costimulation, Checkpoint Inhibitors and Anti-Tumor Therapy","volume":"45","author":"Nandi","year":"2020","journal-title":"J Biosci"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20030916","article-title":"CD27 Promotes Survival of Activated T Cells and Complements CD28 in Generation and Establishment of the Effector T Cell Pool","volume":"198","author":"Hendriks","year":"2003","journal-title":"J Exp Med"},{"key":"B28","doi-asserted-by":"publisher","first-page":"308265","DOI":"10.1100\/2012\/308265","article-title":"CD8+ T Cells: GITR Matters","volume":"2012","author":"Ronchetti","year":"2012","journal-title":"ScientificWorldJournal"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1111\/imm.12028","article-title":"CD26-Mediated Co-Stimulation in Human CD8+ T Cells Provokes Effector Function via Pro-Inflammatory Cytokine Production","volume":"138","author":"Hatano","year":"2013","journal-title":"Immunology"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S145039","article-title":"Axicabtagene Ciloleucel (KTE-C19), an Anti-CD19 CAR T Therapy for the Treatment of Relapsed\/Refractory Aggressive B-Cell non-Hodgkin\u2019s Lymphoma","volume":"14","author":"Jain","year":"2018","journal-title":"Ther Clin Risk Manage"},{"key":"B31","doi-asserted-by":"publisher","first-page":"e1049","DOI":"10.1002\/cti2.1049","article-title":"Selecting Costimulatory Domains for Chimeric Antigen Receptors: Functional and Clinical Considerations","volume":"8","author":"Weinkove","year":"2019","journal-title":"Clin Transl Immunol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V75.3.555.555","article-title":"Graft-Versus-Leukemia Reactions After Bone Marrow Transplantation","volume":"75","author":"Horowitz","year":"1990","journal-title":"Blood"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12378","article-title":"Prevention of Acute Graft-Versus-Host Disease by Humanized Anti-CD26 Monoclonal Antibody","volume":"162","author":"Hatano","year":"2013","journal-title":"Br J Haematol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe2032581","article-title":"Sitagliptin to Prevent Acute Graft-Versus-Host Disease","volume":"384","author":"Martin","year":"2021","journal-title":"N Engl J Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1502181","article-title":"Host-Derived CD70 Suppresses Murine Graft-Versus-Host Disease by Limiting Donor T Cell Expansion and Effector Function","volume":"199","author":"Leigh","year":"2017","journal-title":"J Immunol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"3700","DOI":"10.4049\/jimmunol.1700380","article-title":"T Cell\u2013Derived CD70 Delivers an Immune Checkpoint Function in Inflammatory T Cell Responses","volume":"199","author":"O\u2019Neill","year":"2017","journal-title":"J Immunol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1002\/eji.1830201223","article-title":"CD27 Expression by a Distinct Subpopulation of Human B Lymphocytes","volume":"20","author":"Maurer","year":"1990","journal-title":"Eur J Immunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(00)80172-7","article-title":"Expression of CD27 on Murine Hematopoietic Stem and Progenitor Cells","volume":"12","author":"Wiesmann","year":"2000","journal-title":"Immunity"},{"key":"B39","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1189\/jlb.0610351","article-title":"Role of CD27\/CD70 Pathway of Activation in Immunity and Tolerance","volume":"89","author":"Denoeud","year":"2011","journal-title":"J Leukoc Biol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.164.4.1741","article-title":"CD27-Mediated Activation of Murine NK Cells","volume":"164","author":"Takeda","year":"2000","journal-title":"J Immunol"},{"key":"B41","first-page":"373","volume-title":"14 - T Cell Activation","author":"Mak","year":"2006"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/0165-5728(91)90175-7","article-title":"Elevated Levels of a Soluble Form of the T Cell Activation Antigen CD27 in Cerebrospinal Fluid of Multiple Sclerosis Patients","volume":"35","author":"Hintzen","year":"1991","journal-title":"J Neuroimmunol"},{"key":"B43","first-page":"69","article-title":"The Molecular Control of Regulatory T Cell Induction","volume-title":"Progress in Molecular Biology and Translational Science","author":"Van Nieuwenhuijze","year":"2015"},{"key":"B44","article-title":"Targeting CD70 for Human Therapeutic Use","volume-title":"Advances in Experimental Medicine and Biology","author":"Boursalian","year":"2009"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pharmthera.2015.07.007","article-title":"CD70: An Emerging Target in Cancer Immunotherapy","volume":"155","author":"Jacobs","year":"2015","journal-title":"Pharmacol Ther"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1300868","article-title":"CD70 Is Downregulated by Interaction With CD27","volume":"191","author":"Kuka","year":"2013","journal-title":"J Immunol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200636824","article-title":"Priming of CD8+ Cell Responses by Pathogens Typically Depends on CD70-Mediated Interactions With Dendritic Cells","volume":"37","author":"Schildknecht","year":"2007","journal-title":"Eur J Immunol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020006738","article-title":"Extended Clinical and Immunological Phenotype and Transplant Outcome in CD27 and CD70 Deficiency","volume":"136","author":"Ghosh","year":"2020","journal-title":"Blood"},{"key":"B49","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/j.jaci.2011.11.013","article-title":"CD27 Deficiency Is Associated With Combined Immunodeficiency and Persistent Symptomatic EBV Viremia","volume":"129","author":"van Montfrans","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1900288","article-title":"CD27 Promotes CD4 + Effector T Cell Survival in Response to Tissue Self-Antigen","volume":"203","author":"Remedios","year":"2019","journal-title":"J\u00a0Immunol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1202222","article-title":"CD8 + T Cells Produce the Chemokine CXCL10 in Response to CD27\/CD70 Costimulation To Promote Generation of the CD8 + Effector T Cell Pool","volume":"191","author":"Peperzak","year":"2013","journal-title":"J\u00a0Immunol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1038\/ni.1717","article-title":"CD27 Is a Thymic Determinant of the Balance Between Interferon-\u03b3- and Interleukin 17-Producing \u03b3\u03b4 T Cell Subsets","volume":"10","author":"Ribot","year":"2009","journal-title":"Nat Immunol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1002\/JLB.1HI0219-064R","article-title":"Frontline Science: Late CD27 Stimulation Promotes IL-7r\u03b1 Transcriptional Re-Expression and Memory T Cell Qualities in Effector CD8+ T Cells","volume":"106","author":"Dong","year":"2019","journal-title":"J Leukoc Biol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2015.00064","article-title":"Missing Cells: Pathophysiology, Diagnosis, and Management of (Pan)Cytopenia in Childhood","volume":"3","author":"Erlacher","year":"2015","journal-title":"Front Pediatr"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-016-2608-z","article-title":"Purification of Hematopoietic Stem Cells From Bone Marrow","volume":"95","author":"Tian","year":"2016","journal-title":"Ann Hematol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1038\/ni1174","article-title":"Immune Activation Modulates Hematopoiesis Through Interactions Between CD27 and CD70","volume":"6","author":"Nolte","year":"2005","journal-title":"Nat Immunol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019001079","article-title":"Safety and Activity of Varlilumab, a Novel and First-in-Class Agonist Anti-CD27 Antibody, for Hematologic Malignancies","volume":"4","author":"Ansell","year":"2020","journal-title":"Blood Adv"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noy148.018","article-title":"ATIM-23. Anti-CD27 Agonist Antibody Varlilumab in Combination With Nivolumab for Recurrent Glioblatosma (rGBM): Phase 2 Clinical Trial Results","volume":"20","author":"Reardon","year":"2018","journal-title":"Neuro Oncol"},{"key":"B59","unstructured":"A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers2011"},{"key":"B60","unstructured":"A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors2015"},{"key":"B61","doi-asserted-by":"publisher","first-page":"3001","DOI":"10.1200\/JCO.2018.36.15_suppl.3001","article-title":"Anti-CD27 Agonist Antibody Varlilumab (Varli) With Nivolumab (Nivo) for Colorectal (CRC) and Ovarian (OVA) Cancer: Phase (Ph) 1\/2 Clinical Trial Results","volume":"36","author":"Sanborn","year":"2018","journal-title":"J Clin Oncol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.15_suppl.3007","article-title":"Clinical Results With Combination of Anti-CD27 Agonist Antibody, Varlilumab, With Anti-PD1 Antibody Nivolumab in Advanced Cancer Patients","volume":"35","author":"Sanborn","year":"2017","journal-title":"J Clin Oncol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"TPS7570","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS7570","article-title":"The DIAL Study (Dual Immunomodulation in Aggressive Lymphoma): A Randomized Phase 2 Study of CDX-1127 (Varlilumab) in Combination With Nivolumab in Patients With Relapsed or Refractory Aggressive B-Cell Lymphomas (NCI 10089\/Nct03038672)","volume":"37","author":"Villasboas","year":"2019","journal-title":"J Clin Oncol"},{"key":"B64","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1186\/s13063-018-2996-6","article-title":"RIVA - A Phase IIa Study of Rituximab and Varlilumab in Relapsed or Refractory B-Cell Malignancies: Study Protocol for a Randomized Controlled Trial","volume":"19","author":"Lim","year":"2018","journal-title":"Trials"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31892","article-title":"A Phase 2 Study of Glembatumumab Vedotin, an Antibody-Drug Conjugate Targeting Glycoprotein NMB, in Patients With Advanced Melanoma","volume":"125","author":"Ott","year":"2019","journal-title":"Cancer"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-3057","article-title":"Pd-1 Blockade and Cd27 Stimulation Activate Distinct Transcriptional Programs That Synergize for CD8\u00fe T-Cell\u2013Driven Antitumor Immunity","volume":"24","author":"Buchan","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1700606","article-title":"CD27-Mediated Regulatory T Cell Depletion and Effector T Cell Costimulation Both Contribute to Antitumor Efficacy","volume":"199","author":"Wasiuk","year":"2017","journal-title":"J Immunol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-020-02610-y","article-title":"Development of CDX-527: A Bispecific Antibody Combining PD-1 Blockade and CD27 Costimulation for Cancer Immunotherapy","volume":"69","author":"Vitale","year":"2020","journal-title":"Cancer Immunol Immunother"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00387","article-title":"A Single-Chain-Based Hexavalent CD27 Agonist Enhances T Cell Activation and Induces Anti-Tumor Immunity","volume":"8","author":"Thiemann","year":"2018","journal-title":"Front Oncol"},{"key":"B70","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/j.ccell.2017.11.001","article-title":"Antibody Tumor Targeting Is Enhanced by CD27 Agonists Through Myeloid Recruitment","volume":"32","author":"Turaj","year":"2017","journal-title":"Cancer Cell"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2019-000629","article-title":"New Emerging Targets in Cancer Immunotherapy: CD27 (Tnfrsf7)","volume":"4","author":"Starzer","year":"2020","journal-title":"ESMO Open"},{"key":"B72","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s40425-015-0080-2","article-title":"Characterization of the Human T Cell Response to In Vitro CD27 Costimulation With Varlilumab","volume":"3","author":"Ramakrishna","year":"2015","journal-title":"J Immunother Cancer"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-15-3130","article-title":"CD27 Agonism Plus PD-1 Blockade Recapitulates CD4+ T-Cell Help in Therapeutic Anticancer Vaccination","volume":"76","author":"Ahrends","year":"2016","journal-title":"Cancer Res"},{"key":"B74","doi-asserted-by":"publisher","first-page":"e1502904","DOI":"10.1080\/2162402X.2018.1502904","article-title":"CD27 Stimulation Unveils the Efficacy of Linked Class I\/II Peptide Vaccines in Poorly Immunogenic Tumors by Orchestrating a Coordinated CD4\/CD8 T Cell Response","volume":"7","author":"Riccione","year":"2018","journal-title":"Oncoimmunology"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.4.1442","article-title":"Rapid Establishment of Dendritic Cell Chimerism in Allogeneic Hematopoietic Cell Transplant Recipients","volume":"99","author":"Auffermann-Gretzinger","year":"2002","journal-title":"Blood"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04588.x","article-title":"Phenotype, Function and Chimaerism of Monocyte-Derived Blood Dendritic Cells After Allogeneic Haematopoietic Stem Cell Transplantation","volume":"123","author":"Nachbaur","year":"2003","journal-title":"Br J Haematol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1172\/JCI133909","article-title":"Donor Monocyte\u2013Derived Macrophages Promote Human Acute Graft-Versus-Host Disease","volume":"130","author":"Jardine","year":"2020","journal-title":"J Clin Invest"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.02.0057","article-title":"Allogeneic Stem-Cell Transplantation Using a Reduced-Intensity Conditioning Regimen has the Capacity to Produce Durable Remissions and Long-Term Disease-Free Survival in Patients With High-Risk Acute Myeloid Leukemia and Myelodysplasia","volume":"23","author":"Tauro","year":"2005","journal-title":"J Clin Oncol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2011.05.002","article-title":"Optimizing the Conditioning Regimen for Allogeneic Stem-Cell Transplantation in Acute Myeloid Leukemia; Dose Intensity is Still in Need","volume":"24","author":"Shimoni","year":"2011","journal-title":"Best Pract Research: Clin Haematol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25225","article-title":"Thiotepa, Busulfan and Fludarabine Compared to Busulfan and Cyclophosphamide as Conditioning Regimen for Allogeneic Stem Cell Transplant From Matched Siblings and Unrelated Donors for Acute Myeloid Leukemia","volume":"93","author":"Saraceni","year":"2018","journal-title":"Am J Hematol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.715909\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,10]],"date-time":"2023-01-10T16:47:29Z","timestamp":1673369249000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.715909\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,22]]},"references-count":80,"alternative-id":["10.3389\/fimmu.2021.715909"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.715909","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,22]]},"article-number":"715909"}}